Introduction {#section1-0269881115602487}
============

One of the key criteria in the process of approving a new drug is clinical relevance of the results. Randomized controlled trials (RCTs) are usually limited to several months in length, and sample sizes have been calculated based on surrogate endpoints like drinking behavior, such as abstinence periods or reduction of drinking ([@bibr10-0269881115602487]; [@bibr12-0269881115602487]). Clinical benefits or clinical relevance in terms of reduction of morbidity or mortality have to be established indirectly in most cases as the underlying trials are time-limited (e.g. efficacy trials and safety trials up to 12--15 months; see [@bibr10-0269881115602487]; [@bibr12-0269881115602487]). For abstinence, it has been demonstrated that stable abstinence over such time predicts long term abstinence ([@bibr7-0269881115602487]; [@bibr48-0269881115602487]) and various clinical relevant endpoints such as functionality, co-morbidity, or mortality ([@bibr19-0269881115602487]; [@bibr36-0269881115602487]).

For reduction of drinking, which can be used for evaluating efficacy of treatment with respect to clinical relevance, it seems harder to find a standard. The treatment goal of reduction in drinking is less well established and informed by a lower level of evidence and consensus. For the US, the Food and Drug Administration has proposed the standard of no heavy drinking days ([@bibr8-0269881115602487]; [@bibr12-0269881115602487]; [@bibr40-0269881115602487]). In Europe, the EMA ([@bibr10-0269881115602487]) has created categories of drinking levels associated with different risks for relevant clinical outcomes, mainly based on chronic disease and injury ([@bibr49-0269881115602487]). A recent publication applied principles outlined in the EMA guideline for evaluation of clinical relevance of reduction of alcohol consumption in clinical trials to biomarkers and quality of life measures ([@bibr5-0269881115602487]). Of special importance seems mortality as the most severe endpoint associated with alcohol use disorders in general and alcohol dependence in particular ([@bibr15-0269881115602487]; [@bibr34-0269881115602487], [@bibr35-0269881115602487]). The work of Laramée et al. can be considered as examples ([@bibr13-0269881115602487]; [@bibr20-0269881115602487]) to demonstrate how the differences found in clinical trials ([@bibr45-0269881115602487], [@bibr46-0269881115602487]) would lead to clinically relevant outcomes, if they persisted, or if the effects were found in larger samples (see also [@bibr6-0269881115602487] for a modeling of different outcomes, such as quality-adjusted life years and costs).

All the studies cited above share one assumption: that the risk curves for various disease or cause of death categories (for an overview, please see [@bibr30-0269881115602487]; [@bibr41-0269881115602487]) can actually be applied to changes in consumption by individuals over time. Thus, if 100 g pure alcohol/day is associated with a certain risk for liver disease incidence or liver disease mortality, and 30 g with a lower risk based on epidemiological studies ([@bibr33-0269881115602487]), then it is assumed that if an individual switches from 100 g to 30 g pure alcohol per day, this individual would reduce his or her risk accordingly. While this assumption is plausible, there are not enough studies to show that real reductions by individuals were associated with risk reductions. However, there are enough studies with all-cause mortality. Meta-analyses of these studies have shown that a reduction in drinking (odds ratio \[OR\] = 0.41, 95% CI: 0.34, 0.50), regardless of achieving actual abstinence, was associated with a reduction in average mortality risk after treatment for alcohol dependence, although abstinence showed the strongest association with reduced mortality ([@bibr36-0269881115602487]). We used an indirect approach to estimate the most important indicator for clinical relevance (namely mortality risk) for nalmefene treatment in comparison to a placebo. We are assuming that the reduced drinking levels in the RCTs is maintained on average 3.5 years, which is the average assessment of drinking levels after baseline in the meta-analyses by [@bibr36-0269881115602487]. Because both reduced drinking and abstinence have been associated with a reduced mortality risk in comparison to continued heavy drinking, two scenarios (Scenario I and II) were used to estimate mortality risk.

Methods and materials {#section2-0269881115602487}
=====================

In this report we used participants with a high or very high drinking risk level (DRL, as defined by WHO; [@bibr10-0269881115602487]) at *both* the screening visit (covering drinking in the prior 4 weeks) and the randomization visit, which corresponds to the population indicated for the use of nalmefene (resulting in *n* = 641 from 6-months RCTs and *n* = 183 from the 1-year RCT with at least one valid post-randomization assessment of drinking). In addition to abstinence, the following DRLs were used for patient assessment throughout the RCTs: 1--20 g pure alcohol per day, \>20--40 g, \>40--60 g, \>60 g (women); 1--40 g, \>40--60 g, \>60--100 g, \>100 g (men) for *low*, *medium*, *high*, and *very high* risk, respectively (from [@bibr10-0269881115602487]). Abstinence or low DRL were defined as a reduced drinking at the end of each trial. Missing values were handled using the last observation carried forward for the main analyses (Scenarios I and II). In sensitivity analyses, a mixed model repeated measures (MMRM) was used. Data from the RCTs are displayed in [Tables 1](#table1-0269881115602487){ref-type="table"} and [2](#table2-0269881115602487){ref-type="table"}.

###### 

Drinking risk level at baseline and month 6 from two 6-month double-blind randomized controlled trials.

![](10.1177_0269881115602487-table1)

  Time point           Women (*n* = 217)   Men (*n* = 424)         
  -------------------- ------------------- ----------------- ----- -----
  Baseline                                                         
   High                25                  29                109   91
   Very high           86                  77                102   122
  Month 6                                                          
   Abstinence or low   30                  33                71    96
   Medium or above     81                  73                140   117

Note: Drinking risk level (DRL, low, medium, high, very high) as defined in the Methods section. Missing values were handled using the last observation carried forward.

###### 

Drinking risk level at baseline and month 13 from the 1-year double-blind randomized controlled trials.

![](10.1177_0269881115602487-table2)

  Time point                                                        Women (*n* = 42)   Men (*n* = 141)        
  ----------------------------------------------------------------- ------------------ ----------------- ---- ----
  Baseline                                                                                                    
   High                                                             4                  10                19   63
   Very high                                                        6                  22                13   46
  Month 13^[a](#table-fn2-0269881115602487){ref-type="table-fn"}^                                             
   Abstinence or low                                                3                  19                13   63
   Medium or above                                                  7                  13                19   46

13 months of 28 days.

Note: Drinking risk level (DRL, low, medium, high, very high) as defined in the Methods section. Missing values were handled using the last observation carried forward.

Data sources {#section3-0269881115602487}
------------

We used data from two sources for this analysis.

The first source was data from two double-blind RCTs (NCT00811720; NCT00812461) investigating drinking levels up to 6 months ([@bibr14-0269881115602487]; [@bibr22-0269881115602487]; [@bibr45-0269881115602487]) and one double-blind RCT (NCT00811941) investigating drinking levels up to 1 year ([@bibr46-0269881115602487]) comparing nalmefene versus placebo (both in combination with psychosocial support). All RCTs received ethics approval and all patients gave informed written consent.

Briefly, the two 6-months RCTs were conducted in Germany, Finland, Sweden, and Austria ([@bibr22-0269881115602487]), and in Belgium, Czech Republic, France, Italy, Poland, Portugal, and Spain ([@bibr14-0269881115602487]) from December 2008 to July 2010. The 1-year RCT was conducted between March 2009 and September 2010 in the Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Russia, Slovakia, Ukraine, and the UK ([@bibr46-0269881115602487]). Main eligibility criteria were ([@bibr14-0269881115602487]; [@bibr22-0269881115602487]; [@bibr46-0269881115602487]): ⩾18 years of age, primary diagnosis of alcohol dependence ([@bibr3-0269881115602487]) assessed by the Mini-International Neuropsychiatric Interview ([@bibr21-0269881115602487]), and blood alcohol level \<0.02% at screening.

Main exclusion criteria were ([@bibr14-0269881115602487]; [@bibr22-0269881115602487]; [@bibr46-0269881115602487]): \<6 heavy drinking days (⩾60 g/day for men and ⩾40 g/day for women; [@bibr10-0269881115602487]) in the 4 weeks before screening, average alcohol consumption below medium risk levels (for the two 6-month trials, the 12-month one including low risk levels), \>14 consecutive abstinent days in the 4 weeks before screening, a score ⩾10 (indicating the need for medication-supported detoxification) on the revised version of the Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar; [@bibr44-0269881115602487]), aspartate aminotransferase or alanine aminotransferase values \>3 times of upper normal limit, current DSM-IV Axis 1 disorder other than alcohol dependence, DSM-IV Axis II antisocial personality disorder, or recent (within 1 week prior to the screening) treatment with opioid agonists or partial agonists. In the 1-year RCT, patients with stable comorbid psychiatric disorders were eligible ([@bibr46-0269881115602487]). For a more detailed description of selection criteria, please see supplementary appendices in [@bibr22-0269881115602487], [@bibr46-0269881115602487], and [@bibr14-0269881115602487].

One nalmefene tablet (18 mg) was to be taken on each day when risk of drinking was perceived, preferably 1--2 hours before the anticipated time of drinking. Drinking (daily number of standard drinks) and medication intake throughout the trials were recorded with Timeline Follow-back ([@bibr42-0269881115602487]). Country-specific conversion factors were used to transform drinking into g/day, and patients were provided with a conversion card. In addition to nalmefene or placebo, all participants participated in a motivational and adherence-enhancing intervention (BRENDA, ([@bibr43-0269881115602487]; [@bibr47-0269881115602487])) starting at randomization and at each subsequent site visit. No treatment goal was specified, i.e. abstinence and a reduction in drinking were accepted. Pre-defined primary outcome measures were change from baseline in total alcohol consumption and number of heavy drinking days. A total of 1711 patients were screened, and 1322 patients were randomized to as-needed nalmefene or placebo in the two 6-month RCTs, and 841 patients screened and 675 patients randomized in the 1-year RCT. The majority of these patients had not undergone previous treatment for alcohol dependence or withdrawal symptoms ([@bibr45-0269881115602487], [@bibr46-0269881115602487]).

Secondly, we used data from comprehensive published meta-analyses ([@bibr36-0269881115602487]) as an indicator for mortality risk, and applied the pooled all-cause mortality risk reductions from these meta-analyses to the reductions in alcohol consumption observed in the above mentioned RCTs. In total, data from 16 primary studies were included in these meta-analyses, contributing to 755 observed deaths, with 4951 people at risk ([@bibr36-0269881115602487]). The time from baseline to follow-up of drinking status (abstinence, reduced drinking, or relapse/continued heavy drinking) ranged from 1 to 15 years with a weighted mean of 3.5 years, and the time from baseline to mortality or end of study ranged from 3 to 16 years with a weighted mean of 8.8 years.

In Scenario I, we used pooled mortality risks based on reduced drinking including abstinence versus continued heavy drinking, and in Scenario II we used pooled mortality risks based on reduced drinking excluding abstinence versus continued heavy drinking. In other words: Scenario I used an OR of 0.41 (95% CI: 0.34, 0.50), based on reduced drinking including abstinence versus continued heavy drinking ([@bibr36-0269881115602487]), and Scenario II, a more conservative analysis (considering that some patients became abstinent with nalmefene treatment during RCTs), used an OR of 0.61 (95% CI: 0.39, 0.94), based on reduced drinking excluding abstinence versus continued heavy drinking ([@bibr36-0269881115602487]).

Derivation of mortality risk estimates {#section4-0269881115602487}
--------------------------------------

The data from the RCTs presented in [Table 1](#table1-0269881115602487){ref-type="table"} and [2](#table2-0269881115602487){ref-type="table"} were combined with reported mortality risk estimates by drinking level after alcohol treatment from the meta-analyses of [@bibr36-0269881115602487] using the following formula for relative risk (RR) of mortality of nalmefene versus placebo:

$${Relative\ Risk\ of\ mortality},{nalmefene\ versus\ placebo} = \frac{\sum_{i}p_{na,i}OR_{i}}{\sum_{i}p_{pl,i}OR_{i}}$$

where *p~na,i~* is the prevalence of *DRL~i~* in the nalmefene group, *p~pl,i~* is the prevalence of *DRL~i~* in the placebo group, and *OR~i~* is the OR for *DRL~i~*, which was the same for the nalmefene and placebo groups. With respect to confidence intervals, for each analysis, 100,000 Monte Carlo simulations were computed based on the following approach:

a.  Two sources of uncertainty were entered: the prevalence of the respective category, and the OR,

b.  The uncertainty of prevalence was derived from the SE as $\sqrt{\frac{p(1 - p)}{n}},$

c.  The uncertainty of the OR was based on the meta-analyses from [@bibr36-0269881115602487].

As customary in analyses of OR, it was assumed that the distribution of the logarithmic risk was normally distributed ([@bibr11-0269881115602487]; [@bibr37-0269881115602487]). The relative risks of mortality, nalmefene versus placebo, were pooled across trials using inverse-variance weighted DerSimonian--Laird random-effect models to allow for potential between-study heterogeneity ([@bibr9-0269881115602487]). Sensitivity analyses were performed varying the prevalence estimates from the RCTs with missing values imputed using individual patient-predicted values of total alcohol consumption (g pure alcohol/day) derived from a MMRM used in the primary analysis of total alcohol consumption in the nalmefene RCTs ([@bibr14-0269881115602487]; [@bibr22-0269881115602487]; [@bibr46-0269881115602487]). Between-study heterogeneity was quantified using the I^2^ statistic ([@bibr17-0269881115602487]). All meta-analytical analyses were performed on the natural log scale in Stata statistical software, version 12 (Stata Corp, College Station, Texas).

Results {#section5-0269881115602487}
=======

Scenario I {#section6-0269881115602487}
----------

Assuming an OR of 0.41 (95% CI: 0.34, 0.50) for reduced drinking including abstinence, the 9-year estimated mortality risks in the nalmefene group versus the placebo group after combining the data from the nalmefene RCTs with the data from the meta-analysis are presented in [Figure 1](#fig1-0269881115602487){ref-type="fig"}. The overall treatment effect of nalmefene versus placebo was predicted to reduce the estimated 9-year mortality risk on average by 8% (95% CI: 2%, 13%).

![Mortality risks (nalmefene versus placebo) assuming an OR = 0.41 for reduced drinking (including abstinence).\
Note: I^2^ = 6%, *p* = 0.37 for overall analysis, random-effects model.](10.1177_0269881115602487-fig1){#fig1-0269881115602487}

Scenario II {#section7-0269881115602487}
-----------

Assuming an OR of 0.61 (95% CI: 0.39, 0.94) for reduced drinking (based on studies with data on reduced drinking, excluding studies with only abstinence data; see [@bibr36-0269881115602487]), the mortality risks in the nalmefene group versus the placebo group after combining the data from the nalmefene RCTs with the data from the meta-analysis are presented in [Figure 2](#fig2-0269881115602487){ref-type="fig"}. The overall treatment effect of nalmefene versus placebo was predicted to reduce the estimated 9-year mortality risk on average by 4% (95% CI: 0%, 8%).

![Mortality risks (nalmefene versus placebo) assuming an OR = 0.61 for reduced drinking (excluding abstinence).\
Note: I^2^ = 0%, *p* = 0.54 for overall analysis, random-effects model.](10.1177_0269881115602487-fig2){#fig2-0269881115602487}

Sensitivity analyses {#section8-0269881115602487}
--------------------

Sensitivity analyses were performed using the DRLs with missing values imputed using individual patient-predicted values of total alcohol consumption as described above. For Scenario I, the overall treatment effect of nalmefene versus placebo was predicted to reduce the estimated 9-year mortality risk on average by 9% (RR: 0.91; 95% CI: 0.86, 0.96); and for the Scenario II, the overall treatment effect was 5% (RR: 0.95; 95% CI: 0.91, 0.99). Thus, the predicted mortality reductions were slightly higher when using MMRM imputation for missing values than using a last observation carried forward imputation for handling missing values in the nalmefene RCTs.

Discussion {#section9-0269881115602487}
==========

Before discussing the results and implications of the study, we would like to point out potential limitations.

Limitations {#section10-0269881115602487}
-----------

Data included in the original meta-analysis on reduced drinking were derived from 16 published studies with various definitions of reduced drinking, including abstinence. The *low* DRL can be seen as a conservative interpretation of reduced drinking; many of the studies included in the original meta-analyses by [@bibr36-0269881115602487] had more lenient definitions and higher thresholds as reduced drinking after alcohol treatment. Thus, it is justified to use *low* DRL to define reduced drinking. However, while the definition of reduced drinking is conservative with medium DRL considered as no improvement in heavy drinking, the proportion of abstainers in the studies included in the meta-analyses of [@bibr36-0269881115602487] was higher than that in the nalmefene RCTs. Therefore, Scenario II was performed using the OR for reduced drinking excluding abstinence (based on studies with data on reduced drinking, excluding studies with only abstinence data; see [@bibr36-0269881115602487]). This estimate is conservative, as there were abstinence outcomes observed in the nalmefene RCTs. Furthermore, we are assuming that any reduction in drinking during the RCTs is maintained after the conclusion of the trials. The mean assessment of drinking status after treatment was 3.5 years in the meta-analyses used to estimate mortality risks associated with a reduction in drinking levels, and mortality was ascertained after a mean of 8.8 years after baseline. The second assumption is that the RCTs and studies included in the meta-analyses have comparable populations. While all participants in both RCTs and the meta-analyses received treatment for alcohol use disorders, many of the studies in the meta-analyses were from an in-patient treatment setting and thus may comprise of more severe cases of alcohol use disorders. However, no other systematic examinations have been published and thus we used the best data available for our study.

Implications {#section11-0269881115602487}
------------

While clinical studies with usual 6 months duration cannot show clinical relevance on major outcomes such as mortality, combining trial data on reduction in drinking levels and mortality risks associated with such reductions allowed the estimation of clinical relevance. In short, we could show that the reduction of drinking following treatment with nalmefene versus placebo had clinical relevance with respect to mortality, when combined with results from meta-analyses of all relevant clinical studies. In other words: the relative drinking level reductions observed in patients with a high or very high DRL at screening and randomization between compared arms from the nalmefene RCTs ([@bibr14-0269881115602487]; [@bibr22-0269881115602487]; [@bibr45-0269881115602487], [@bibr46-0269881115602487]) are large enough to expect reduced mortality in the future. The question is, how the effect size of the present study compares to other effect sizes. First, the effect sizes of pharmacological treatment for alcohol use disorders in general compare favorable to the effects of other treatments such as psychotherapy ([@bibr25-0269881115602487]; [@bibr32-0269881115602487]). The only intervention with higher mortality gains would be brief interventions in certain hospital settings, i.e. for people with high risk of mortality ([@bibr24-0269881115602487]; [@bibr27-0269881115602487]). Second, the absolute gain for society would be huge in regions like Europe, where more than 3% of the adult population fulfill the criteria of alcohol dependence ([@bibr28-0269881115602487]), and most of them would fulfill the criteria of high or very high DRL ([@bibr29-0269881115602487]). Finally, the effect size against placebo of the underlying studies was similar to effect sizes for other treatments, e.g. for depression treatment (effect size: numbers needed to treat; [@bibr4-0269881115602487]).

While the expected reductions of mortality are relatively small, any statistically significant reduction of mortality is important, especially given the high mortality risk associated with patients in alcohol treatment ([@bibr34-0269881115602487]). The results also indicate that reduction of drinking can be clinically relevant on the long term, even if drinking levels are not reduced to abstinence. This result is important, since many people with alcohol use disorders either are unable or do not want to choose abstinence as a treatment goal and some of them will not attend treatment for that reason (e.g., [@bibr16-0269881115602487]; [@bibr18-0269881115602487]). On the other hand, treatment goal and results may change during treatment or post-treatment, and reduction of drinking was not necessarily associated with less long-term success (see also [@bibr2-0269881115602487]; [@bibr38-0269881115602487]; [@bibr39-0269881115602487]). The proportion of people with alcohol use disorders receiving treatment overall is low ([@bibr1-0269881115602487], [@bibr23-0269881115602487]; [@bibr31-0269881115602487]), and important public health improvements could be made, if more people sought treatment ([@bibr32-0269881115602487]). The presented results clearly support this line of reasoning (see also [@bibr26-0269881115602487]), and it is hoped that the introduction of pharmacological agents such as nalmefene will lead to higher treatment rates and better survival of people with alcohol dependence.
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